NEW YORK — Novacyt reported on Thursday a four percent drop in revenues for 2019, alongside a 40 percent jump in its total net loss for the year. The French diagnostics firm downplayed the impact of the results, however, citing surging demand for its SARS-CoV-2 test.
That qPCR-based test was launched in late January and sales, orders, and commitments for its purchase have "significantly exceeded expectations," Novacyt said. As a result, 2019's financial results "do not have a material bearing on the current business."